We therefore sought to determine if one of the second-generation MDM2 inhibitors [33], MI-63 [34], [35], could be active against myeloma, and if it could fit into our armamentarium in combination with other currently approved and novel agents against this disease. Here, MDM2 is linked to plasma cell myeloma.